ObsEva Announces Second Quarter 2020 Financial Results and Business Update

Primary endpoint successfully met in Phase 3PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids

Phase 3 data from PRIMROSE 2 trial demonstrated sustained efficacy and continued safety over 52 weeks of treatment with linzagolix,including bone mineral density changesA  A 

Phase 3 trial results support the advancement of linzagolix 100 mg without add-back therapy and 200 mg with add-back therapy doses to regulatory submissions planned for Q4:20/H1:21 in Europe/U.S.

Actively discussing commercial partnership to maximize linzagolix best-in-class potential

OBE022 Phase 2 PROLONG trial results on track for Q4:20

YuYuan Bioscience Technology submitted pre-IND meeting request for nolasiban development in China A 

A A A A A A A A A A A A A A A A A A A A A A A  GENEVA, Switzerland and BOSTON, MA (August 6, 2020) a?? ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a late clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve womena??s reproductive health, today reported financial results for the quarter ended June 30, 2020 and provided a business update."The excellent phase 3 results from PRIMROSE 1 and PRIMROSE 2 last month were critical achievements as we now embark upon regulatory filings and commercial preparationa??, said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva. a??We strongly believe that our strategy to develop both a low dose of linzagolix without hormonal add back therapy and a high dose with hormonal add back therapy is the optimal way to treat more women suffering from heavy menstrual bleeding due to uterine fibroids.a??A 
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »